Associated High Confidence AOPs |
---|
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:3 | Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits | Nervous System Disease | WPHA/WNT Endorsed | 0.43 | KE:177 | Mitochondrial dysfunction |
KE:188 | Neuroinflammation | |||||
KE:887 | Inhibition, NADH-ubiquinone oxidoreductase (complex I) | |||||
AOP:4 | Ecdysone receptor agonism leading to incomplete ecdysis associated mortality | Unclassified | - | 0.3 | KE:1264 | Increase, Nuclear receptor E75b gene expression |
KE:993 | Decrease, Abdominal muscle contraction | |||||
KE:1265 | Increase, Fushi tarazu factor-1 gene expression | |||||
AOP:8 | Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Nervous System Disease | Under Development | 0.22 | KE:757 | Hippocampal anatomy, Altered |
KE:756 | Hippocampal gene expression, Altered | |||||
AOP:10 | Binding to the picrotoxin site of ionotropic GABA receptors leading to epileptic seizures in adult brain | Nervous System Disease | WPHA/WNT Endorsed | 0.17 | KE:616 | Occurrence, A paroxysmal depolarizing shift |
AOP:15 | Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations | Genetic Disease | WPHA/WNT Endorsed | 0.25 | KE:155 | Inadequate DNA repair |
AOP:18 | PPARα activation in utero leading to impaired fertility in males | Reproductive System Disease | Under Review | 0.5 | KE:413 | Reduction, Testosterone synthesis in Leydig cells |
KE:447 | Reduction, Cholesterol transport in mitochondria | |||||
KE:266 | Decrease, Steroidogenic acute regulatory protein (STAR) | |||||
KE:289 | Decrease, Translocator protein (TSPO) | |||||
AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | 0.4 | KE:317 | Altered, Cardiovascular development/function |
KE:1269 | Increase, COX-2 expression | |||||
AOP:23 | Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) | Unclassified | WPHA/WNT Endorsed | 0.4 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:274 | Reduction, Testosterone synthesis by ovarian theca cells | |||||
KE:285 | Reduction, Vitellogenin synthesis in liver | |||||
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
AOP:25 | Aromatase inhibition leading to reproductive dysfunction | Unclassified | WPHA/WNT Endorsed | 0.38 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:285 | Reduction, Vitellogenin synthesis in liver | |||||
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal System Disease | Under Development | 0.38 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:288 | Activation of specific nuclear receptors, Transcriptional change | |||||
AOP:30 | Estrogen receptor antagonism leading to reproductive dysfunction | Unclassified | Under Review | 0.17 | KE:285 | Reduction, Vitellogenin synthesis in liver |
AOP:36 | Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.12 | KE:140 | Decreased, HSD17B10 expression |
AOP:38 | Protein Alkylation leading to Liver Fibrosis | Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.29 | KE:68 | Accumulation, Collagen |
KE:1493 | Increased Pro-inflammatory mediators | |||||
AOP:39 | Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response | Respiratory System Disease | Under Development | 0.2 | KE:272 | Activation/Proliferation, T-cells |
AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal System Disease | Under Review | 0.6 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | |||||
KE:139 | N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects | |||||
AOP:58 | NR1I3 (CAR) suppression leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.25 | KE:462 | Up Regulation, SCD-1 |
KE:454 | Increased, Triglyceride formation | |||||
KE:463 | Up Regulation, FAS | |||||
KE:54 | Up Regulation, CD36 | |||||
AOP:60 | NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.42 | KE:454 | Increased, Triglyceride formation |
KE:54 | Up Regulation, CD36 | |||||
KE:462 | Up Regulation, SCD-1 | |||||
KE:474 | Down Regulation, HMGCS2 | |||||
KE:472 | Down Regulation, CPT1A | |||||
AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive System Disease | - | 0.29 | KE:413 | Reduction, Testosterone synthesis in Leydig cells |
KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells | |||||
AOP:73 | Xenobiotic Inhibition of Dopamine-beta-Hydroxylase and subsequent reduced fecundity | Unclassified | - | 0.15 | KE:10059 | Decreased LH surge for 24 hours |
KE:531 | Decreased, LH Surge | |||||
AOP:77 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 | Unclassified | - | 0.29 | KE:177 | Mitochondrial dysfunction |
KE:341 | Impairment, Learning and memory | |||||
AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | 0.25 | KE:177 | Mitochondrial dysfunction |
KE:341 | Impairment, Learning and memory | |||||
AOP:79 | Nicotinic acetylcholine receptor activation contributes to impaired hive thermoregulation and leads to colony loss/failure | Unclassified | - | 0.2 | KE:177 | Mitochondrial dysfunction |
AOP:80 | Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure | Unclassified | - | 0.25 | KE:177 | Mitochondrial dysfunction |
KE:664 | Overwhelmed, Mitochondrial DNA repair mechanisms | |||||
AOP:87 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure | Unclassified | - | 0.25 | KE:177 | Mitochondrial dysfunction |
KE:341 | Impairment, Learning and memory | |||||
AOP:88 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:89 | Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:94 | Sodium channel inhibition leading to congenital malformations | Unclassified | - | 0.17 | KE:445 | Respiratory distress/arrest |
AOP:102 | Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition | Reproductive System Disease | - | 0.1 | KE:690 | Reduced, Luteinizing hormone (LH), plasma |
AOP:103 | Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint | Reproductive System Disease | - | 0.1 | KE:690 | Reduced, Luteinizing hormone (LH), plasma |
AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.14 | KE:739 | Increase, Hypertrophy and proliferation (follicular cell) |
AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive System Disease; Cancer | - | 0.33 | KE:747 | Decreased, Prolactin |
KE:749 | Decreased, Progesterone from corpus luteum | |||||
AOP:114 | HPPD inhibition leading to corneal papillomas and carcinomas (in rat) | Cancer | - | 0.33 | KE:777 | Increase, Inflammation (corneal cells) |
KE:778 | Increase, Regenerative cell proliferation (corneal cells) | |||||
AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | 0.4 | KE:149 | Increase, Inflammation |
KE:781 | Increase, Regenerative cell proliferation (forestomach epithelial cells) | |||||
AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.14 | KE:739 | Increase, Hypertrophy and proliferation (follicular cell) |
AOP:122 | Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation | Unclassified | - | 0.4 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:799 | Increased, HIF-1 heterodimer | |||||
KE:285 | Reduction, Vitellogenin synthesis in liver | |||||
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | 0.45 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:802 | Increased, HIF-1 alpha transcription | |||||
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
KE:285 | Reduction, Vitellogenin synthesis in liver | |||||
KE:799 | Increased, HIF-1 heterodimer | |||||
AOP:126 | Alpha-noradrenergic antagonism leads to reduced fecundity via delayed ovulation | Unclassified | - | 0.15 | KE:10059 | Decreased LH surge for 24 hours |
KE:531 | Decreased, LH Surge | |||||
AOP:130 | Phospholipase A2 (LPLA2) inhibitors leading to hepatotoxicity | Gastrointestinal System Disease | Under Development | 0.09 | KE:177 | Mitochondrial dysfunction |
AOP:131 | Aryl hydrocarbon receptor activation leading to uroporphyria | Inherited Metabolic Disorder | WPHA/WNT Endorsed | 0.17 | KE:850 | Induction, CYP1A2/CYP1A5 |
AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign Neoplasm; Respiratory System Disease | Under Review | 0.29 | KE:768 | Increase, Cytotoxicity |
KE:870 | Increase, Cell Proliferation | |||||
AOP:144 | Endocytic lysosomal uptake leading to liver fibrosis | Gastrointestinal System Disease | Under Review | 0.33 | KE:68 | Accumulation, Collagen |
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:177 | Mitochondrial dysfunction | |||||
AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | 0.29 | KE:317 | Altered, Cardiovascular development/function |
KE:948 | reduced production, VEGF | |||||
AOP:164 | Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | Cancer; Reproductive System Disease | - | 0.33 | KE:1043 | Hypertrophy/hyperplasia, smooth muscle |
KE:1042 | Proliferation/Clonal Expansion, smooth muscle | |||||
AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive System Disease; Cancer | - | 0.29 | KE:1066 | Promotion, SIX-1 postive basal-type progenitor cells |
KE:1067 | Proliferation/Clonal Expansion, aberrant basal cells | |||||
AOP:173 | Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | WPHA/WNT Endorsed | 0.25 | KE:68 | Accumulation, Collagen |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:201 | Juvenile hormone receptor agonism leading to male offspring induction associated population decline | Unclassified | - | 0.17 | KE:1206 | Induction, Doublesex1 gene |
AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.17 | KE:149 | Increase, Inflammation |
AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive System Disease | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:177 | Mitochondrial dysfunction | |||||
KE:1262 | Apoptosis | |||||
KE:1281 | Increased, DNA Damage-Repair | |||||
AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive System Disease | WPHA/WNT Endorsed | 0.33 | KE:1262 | Apoptosis |
KE:1505 | Cell cycle, disrupted | |||||
AOP:213 | Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:219 | Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior | Unclassified | - | 0.17 | KE:1390 | Sexual behavior, decreased |
AOP:241 | Latent Transforming Growth Factor beta1 activation leads to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | - | 0.17 | KE:68 | Accumulation, Collagen |
AOP:256 | Inhibition of mitochondrial DNA polymerase gamma leading to kidney toxicity | Urinary System Disease | Under Development | 0.2 | KE:177 | Mitochondrial dysfunction |
AOP:258 | Renal protein alkylation leading to kidney toxicity | Urinary System Disease | Under Development | 0.4 | KE:40 | Decrease, Mitochondrial ATP production |
KE:177 | Mitochondrial dysfunction | |||||
AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | 0.2 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
AOP:276 | Inhibition of complex I of the electron transport chain leading to chemical induced Fanconi syndrome | Urinary System Disease | - | 0.17 | KE:887 | Inhibition, NADH-ubiquinone oxidoreductase (complex I) |
AOP:280 | α-diketone-induced bronchiolitis obliterans | Musculoskeletal System Disease; Respiratory System Disease | - | 0.14 | KE:149 | Increase, Inflammation |
AOP:289 | Inhibition of 5α-reductase leading to impaired fecundity in female fish | Unclassified | Under Development | 0.17 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
AOP:299 | Deposition of energy leading to population decline via DNA oxidation and follicular atresia | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:305 | 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.2 | KE:286 | Altered, Transcription of genes by the androgen receptor |
AOP:306 | Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.25 | KE:286 | Altered, Transcription of genes by the androgen receptor |
AOP:309 | Luteinizing hormone receptor antagonism leading to reproductive dysfunction | Unclassified | - | 0.29 | KE:1693 | Reduction, Plasma progesterone concentration |
KE:1692 | Reduction, Progesterone synthesis | |||||
AOP:310 | Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR | Unclassified | - | 0.25 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:285 | Reduction, Vitellogenin synthesis in liver | |||||
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
AOP:311 | Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:318 | Glucocorticoid Receptor activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.2 | KE:291 | Accumulation, Triglyceride |
AOP:321 | Reduced environmental pH leading to thinner shells in Mytilus edulis | Unclassified | - | 0.18 | KE:592 | Reduced, survival |
KE:10042 | Abnormal development | |||||
AOP:323 | PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone | Unclassified | - | 0.17 | KE:807 | Decreased, cholesterol |
AOP:344 | Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring | Unclassified | Under Development | 0.25 | KE:286 | Altered, Transcription of genes by the androgen receptor |
AOP:345 | Androgen receptor (AR) antagonism leading to decreased fertility in females | Endocrine System Disease; Reproductive System Disease; Reproductive System Disease | Under Development | 0.17 | KE:286 | Altered, Transcription of genes by the androgen receptor |
AOP:346 | Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:1789 | Reduction, 17beta-estradiol synthesis by the undifferentiated gonad |
AOP:362 | Immune mediated hepatitis | Gastrointestinal System Disease; Immune System Disease | - | 0.12 | KE:177 | Mitochondrial dysfunction |
AOP:372 | Androgen receptor antagonism leading to testicular cancer | Endocrine System Disease; Reproductive System Disease; Cancer | - | 0.2 | KE:286 | Altered, Transcription of genes by the androgen receptor |
AOP:374 | Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis | Nervous System Disease | Under Development | 0.5 | KE:188 | Neuroinflammation |
KE:352 | N/A, Neurodegeneration | |||||
AOP:382 | Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:68 | Accumulation, Collagen | |||||
AOP:383 | Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis | Gastrointestinal System Disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:386 | Deposition of ionizing energy leading to population decline via inhibition of photosynthesis | Reproductive System Disease | - | 0.12 | KE:1115 | Increase, Reactive oxygen species |
AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive System Disease | - | 0.25 | KE:40 | Decrease, Mitochondrial ATP production |
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:394 | SARS-CoV-2 infection of olfactory epithelium leading to impaired olfactory function (short-term anosmia) | Endocrine System Disease | Under Development | 0.14 | KE:1847 | Increased SARS-CoV-2 production |
AOP:397 | Bulky DNA adducts leading to mutations | Genetic Disease | Under Development | 0.33 | KE:155 | Inadequate DNA repair |
AOP:428 | Binding of S-protein to ACE2 in enterocytes induces ACE2 dysregulation leading to gut dysbiosis | Gastrointestinal System Disease | Under Development | 0.33 | KE:1854 | Dysregulation, ACE2 expression and activity |
AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic System Disease; Cancer | - | 0.27 | KE:870 | Increase, Cell Proliferation |
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:155 | Inadequate DNA repair | |||||
AOP:437 | Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity | Urinary System Disease | Under Development | 0.4 | KE:177 | Mitochondrial dysfunction |
KE:1392 | Oxidative Stress | |||||
AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic Disease; Cancer | Under Development | 0.44 | KE:149 | Increase, Inflammation |
KE:1971 | Increased, tumor growth | |||||
KE:1262 | Apoptosis | |||||
KE:1241 | Increased, Motility | |||||
AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign Neoplasm; Endocrine System Disease; Reproductive System Disease; Reproductive System Disease; Cancer; Endocrine System Disease | Under Development | 0.11 | KE:1052 | Hyperplasia, ovarian epithelium |
AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital Nervous System Abnormality; Nervous System Disease | - | 0.14 | KE:1262 | Apoptosis |
AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic Disease; Cancer | Under Development | 0.2 | KE:1554 | Increase Chromosomal Aberrations |
KE:155 | Inadequate DNA repair | |||||
AOP:444 | Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability | Unclassified | - | 0.11 | KE:1392 | Oxidative Stress |
AOP:455 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development | Musculoskeletal System Disease | Under Review | 0.33 | KE:2020 | Decrease, sox9 expression |
KE:2021 | Increase, slincR expression | |||||
AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | 0.5 | KE:2020 | Decrease, sox9 expression |
KE:317 | Altered, Cardiovascular development/function | |||||
KE:2021 | Increase, slincR expression | |||||
AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | 0.33 | KE:1821 | Decrease, Cell proliferation |
KE:1262 | Apoptosis | |||||
KE:2040 | Decrease, GLI1/2 target gene expression | |||||
AOP:464 | Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits | Nervous System Disease | - | 0.11 | KE:177 | Mitochondrial dysfunction |
KE:1392 | Oxidative Stress | |||||
AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.12 | KE:2050 | Increase, developmental abnormalities |
AOP:467 | Knickkopf leading to mortality | Unclassified | - | 0.11 | KE:2050 | Increase, developmental abnormalities |
AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular System Disease | Under Review | 0.25 | KE:1493 | Increased Pro-inflammatory mediators |
KE:1392 | Oxidative Stress | |||||
AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous System Disease; Monogenic Disease | Under Review | 0.4 | KE:870 | Increase, Cell Proliferation |
KE:1636 | Increase, Chromosomal aberrations | |||||
KE:155 | Inadequate DNA repair | |||||
KE:1392 | Oxidative Stress | |||||
AOP:479 | Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress | Cardiovascular System Disease; Thoracic Disease | Under Development | 0.43 | KE:177 | Mitochondrial dysfunction |
KE:1532 | Decrease, Cardiac contractility | |||||
KE:1392 | Oxidative Stress | |||||
AOP:480 | Mitochondrial complexes inhibition leading to heart failure via decreased ATP production | Cardiovascular System Disease; Thoracic Disease | Under Development | 0.6 | KE:40 | Decrease, Mitochondrial ATP production |
KE:177 | Mitochondrial dysfunction | |||||
KE:1532 | Decrease, Cardiac contractility | |||||
AOP:482 | Deposition of energy leading to occurrence of bone loss | Musculoskeletal System Disease | Under Review | 0.14 | KE:1392 | Oxidative Stress |
AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive System Disease | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1445 | Increase, Lipid peroxidation | |||||
AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired Metabolic Disease | - | 0.3 | KE:1497 | Increased, recruitment of inflammatory cells |
KE:2125 | Increased fat mass | |||||
KE:2119 | Insulin resistance, increased | |||||
AOP:496 | Androgen receptor agonism leading to reproduction dysfunction (in zebrafish) | Unclassified | - | 0.2 | KE:286 | Altered, Transcription of genes by the androgen receptor |
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | 0.33 | KE:2251 | Estradiol availability, increased |
AOP:507 | Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway | Cardiovascular System Disease | - | 0.17 | KE:1392 | Oxidative Stress |
AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular System Disease | - | 0.29 | KE:177 | Mitochondrial dysfunction |
KE:1392 | Oxidative Stress | |||||
AOP:510 | Demethylation of PPAR promotor leading to vascular disrupting effects | Cardiovascular System Disease | - | 0.1 | KE:1392 | Oxidative Stress |
AOP:517 | Pregnane X Receptor (PXR) activation leads to liver steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.4 | KE:291 | Accumulation, Triglyceride |
KE:54 | Up Regulation, CD36 | |||||
AOP:518 | Liver X Receptor (LXR) activation leads to liver steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.2 | KE:291 | Accumulation, Triglyceride |
AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | 0.43 | KE:1115 | Increase, Reactive oxygen species |
KE:1445 | Increase, Lipid peroxidation | |||||
KE:1392 | Oxidative Stress | |||||
AOP:524 | Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals | Immune System Disease; Gastrointestinal System Disease | - | 0.11 | KE:1931 | Intestinal barrier, disruption |
AOP:529 | Perfluorooctanesulfonic acid (PFOS) binding to peroxisome proliferator-activated receptors (PPARs) causes dysregulation of lipid metabolism and subsequent liver steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.25 | KE:291 | Accumulation, Triglyceride |
KE:2224 | Dysregulation of transcriptional expression within PPAR signaling network | |||||
AOP:531 | VEGFR inhibition leading to Keratinocyte differentiation-associate Hand-foot skin reaction | Unclassified | - | 0.12 | KE:11005 | Hyperkeratosis |
AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.2 | KE:307 | Increase, Vitellogenin synthesis in liver |
AOP:544 | Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation | Nervous System Disease | - | 0.17 | KE:149 | Increase, Inflammation |
AOP:549 | Aromatase inhibition leads to reproductive toxicity (including growth and developmental toxicity) in adult female zebrafish | Unclassified | - | 0.12 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | 0.4 | KE:2251 | Estradiol availability, increased |
KE:2294 | Plasma estradiol, increased | |||||
AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive System Disease; Endocrine System Disease | - | 0.17 | KE:1262 | Apoptosis |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:6 | Antagonist binding to PPARα leading to body-weight loss | Symptom | WPHA/WNT Endorsed | 0.12 | KE:864 | Decreased, Body Weight |
AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous System Disease; Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.5 | KE:188 | Neuroinflammation |
KE:341 | Impairment, Learning and memory | |||||
KE:352 | N/A, Neurodegeneration | |||||
KE:381 | Reduced levels of BDNF | |||||
AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.2 | KE:341 | Impairment, Learning and memory |
KE:381 | Reduced levels of BDNF | |||||
AOP:16 | Acetylcholinesterase inhibition leading to acute mortality | Unclassified | Under Development | 0.29 | KE:445 | Respiratory distress/arrest |
KE:351 | Increased Mortality | |||||
AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.4 | KE:1493 | Increased Pro-inflammatory mediators |
KE:188 | Neuroinflammation | |||||
KE:341 | Impairment, Learning and memory | |||||
KE:1392 | Oxidative Stress | |||||
AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive System Disease | - | 0.4 | KE:286 | Altered, Transcription of genes by the androgen receptor |
KE:337 | N/A, Impairment of reproductive capacity | |||||
AOP:28 | Cyclooxygenase inhibition leading reproductive failure | Reproductive System Disease | - | 0.17 | KE:253 | N/A, Reproductive failure |
AOP:34 | LXR activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.38 | KE:345 | N/A, Liver Steatosis |
KE:177 | Mitochondrial dysfunction | |||||
KE:291 | Accumulation, Triglyceride | |||||
KE:54 | Up Regulation, CD36 | |||||
KE:258 | Activation, SCD-1 | |||||
AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal System Disease | Under Development | 0.4 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
KE:716 | Increase, cell proliferation (hepatocytes) | |||||
AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary System Disease | WPHA/WNT Endorsed | 0.4 | KE:827 | sensitisation, skin |
KE:272 | Activation/Proliferation, T-cells | |||||
AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | WPHA/WNT Endorsed | 0.38 | KE:757 | Hippocampal anatomy, Altered |
KE:402 | Cognitive function, decreased | |||||
KE:756 | Hippocampal gene expression, Altered | |||||
AOP:43 | Disruption of VEGFR Signaling Leading to Developmental Defects | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:1001 | Increased, Developmental Defects |
AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.44 | KE:177 | Mitochondrial dysfunction |
KE:188 | Neuroinflammation | |||||
KE:341 | Impairment, Learning and memory | |||||
KE:352 | N/A, Neurodegeneration | |||||
AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.2 | KE:341 | Impairment, Learning and memory |
KE:381 | Reduced levels of BDNF | |||||
AOP:91 | Sodium channel inhibition leading to reduced survival | Unclassified | - | 0.17 | KE:592 | Reduced, survival |
AOP:95 | Ether-a-go-go (ERG) voltage-gated potassium channel inhibition leading to reduced survival | Unclassified | - | 0.17 | KE:592 | Reduced, survival |
AOP:96 | Axonal sodium channel modulation leading to acute mortality | Unclassified | - | 0.5 | KE:599 | prolonged, Depolarization of neuronal membrane |
KE:602 | Increased, Ataxia, paralysis, or hyperactivity | |||||
KE:351 | Increased Mortality | |||||
AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | 0.29 | KE:636 | Decreased, survival |
KE:341 | Impairment, Learning and memory | |||||
AOP:104 | Altered ion channel activity leading impaired heart function | Unclassified | - | 0.5 | KE:699 | Increased, cardiac arrthymia |
KE:351 | Increased Mortality | |||||
AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.33 | KE:713 | Increase, Adenomas/carcinomas (renal tubular) |
KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) | |||||
AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal System Disease | Under Review | 0.6 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
KE:1214 | Altered gene expression specific to CAR activation, Hepatocytes | |||||
KE:716 | Increase, cell proliferation (hepatocytes) | |||||
AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.5 | KE:768 | Increase, Cytotoxicity |
KE:719 | Increase, hepatocellular adenomas and carcinomas | |||||
KE:769 | Increase, Oxidative metabolism | |||||
AOP:109 | Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) | Cancer; Respiratory System Disease | - | 0.4 | KE:736 | Increase, Adenomas/carcinomas (bronchioloalveolar) |
KE:734 | Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) | |||||
AOP:113 | Glutamate-gated chloride channel activation leading to acute mortality | Unclassified | - | 0.33 | KE:764 | N/A, Ataxia, paralysis, or hyperactivity |
KE:351 | Increased Mortality | |||||
AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.5 | KE:713 | Increase, Adenomas/carcinomas (renal tubular) |
KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) | |||||
AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | Under Development | 0.5 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
KE:716 | Increase, cell proliferation (hepatocytes) | |||||
AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive System Disease | - | 0.33 | KE:330 | Decrease, Fertility |
KE:807 | Decreased, cholesterol | |||||
AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.33 | KE:757 | Hippocampal anatomy, Altered |
KE:402 | Cognitive function, decreased | |||||
KE:756 | Hippocampal gene expression, Altered | |||||
AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | 0.5 | KE:885 | Increase, Cancer |
KE:155 | Inadequate DNA repair | |||||
AOP:148 | EGFR Activation Leading to Decreased Lung Function | Respiratory System Disease | Under Development | 0.5 | KE:1250 | Decrease, Lung function |
KE:962 | Increase, Mucin production | |||||
AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular System Disease | Under Development | 0.3 | KE:937 | KE7 : Impaired, Vasodilation |
KE:952 | Hypertension | |||||
KE:933 | KE6 : Depletion, Nitric Oxide | |||||
AOP:151 | AhR activation leading to preeclampsia | Cardiovascular System Disease | Under Development | 0.29 | KE:1893 | increase, Preeclampsia |
KE:948 | reduced production, VEGF | |||||
AOP:155 | Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.17 | KE:351 | Increased Mortality |
AOP:156 | Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.17 | KE:351 | Increased Mortality |
AOP:157 | Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.17 | KE:351 | Increased Mortality |
AOP:158 | Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.17 | KE:351 | Increased Mortality |
AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.12 | KE:351 | Increased Mortality |
AOP:160 | Ionotropic gamma-aminobutyric acid receptor activation mediated neurotransmission inhibition leading to mortality | Unclassified | - | 0.14 | KE:351 | Increased Mortality |
AOP:161 | Glutamate-gated chloride channel activation leading to neurotransmission inhibition associated mortality | Unclassified | - | 0.14 | KE:351 | Increased Mortality |
AOP:196 | Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation | Respiratory System Disease | - | 0.11 | KE:1226 | Increased Respiratory irritability and Chronic Cough, |
AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.8 | KE:1393 | Hepatocytotoxicity |
KE:1394 | Induction, persistent proliferation/sustained proliferation | |||||
KE:1395 | Liver Cancer | |||||
KE:1392 | Oxidative Stress | |||||
AOP:237 | Substance interaction with lung resident cell membrane components leading to atherosclerosis | Cardiovascular System Disease | Under Development | 0.2 | KE:1443 | Atherosclerosis |
AOP:242 | Inhibition of lysyl oxidase leading to enhanced chronic fish toxicity | Unclassified | - | 0.12 | KE:636 | Decreased, survival |
AOP:245 | Reduction in photophosphorylation leading to growth inhibition in aquatic plants | Unclassified | - | 0.18 | KE:40 | Decrease, Mitochondrial ATP production |
KE:1521 | Decrease, Growth | |||||
AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous System Disease | - | 0.29 | KE:1514 | Neurodegeneration |
KE:1392 | Oxidative Stress | |||||
AOP:261 | L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility | Cardiovascular System Disease | Under Development | 0.25 | KE:1532 | Decrease, Cardiac contractility |
KE:1535 | Heart failure | |||||
AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.17 | KE:10013 | Impaired growth and development |
AOP:270 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired locomotor activity | Unclassified | - | 0.12 | KE:10016 | Impaired locomotor activity |
AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | 0.57 | KE:870 | Increase, Cell Proliferation |
KE:1556 | Increase, lung cancer | |||||
KE:155 | Inadequate DNA repair | |||||
KE:1636 | Increase, Chromosomal aberrations | |||||
AOP:275 | Histone deacetylase inhibition leads to neural tube defects | Neural Tube Defect | - | 0.4 | KE:1561 | Neural tube defects |
KE:1239 | Altered, Gene Expression | |||||
AOP:279 | Microtubule interacting drugs lead to peripheral neuropathy | Nervous System Disease | - | 0.25 | KE:1583 | Sensory axonal peripheral neuropathy |
AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous System Disease | - | 0.1 | KE:352 | N/A, Neurodegeneration |
AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1521 | Decrease, Growth | |||||
AOP:287 | Mitochondrial complex III antagonism leading to growth inhibition (2) | Unclassified | - | 0.25 | KE:1521 | Decrease, Growth |
AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1521 | Decrease, Growth | |||||
AOP:291 | Mitochondrial ATP synthase antagonism leading to growth inhibition (2) | Unclassified | - | 0.25 | KE:1521 | Decrease, Growth |
AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.33 | KE:1493 | Increased Pro-inflammatory mediators |
KE:1193 | N/A, Breast Cancer | |||||
KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | |||||
AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.33 | KE:1493 | Increased Pro-inflammatory mediators |
KE:1193 | N/A, Breast Cancer | |||||
KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | |||||
AOP:296 | Oxidative DNA damage leading to chromosomal aberrations and mutations | Genetic Disease; Chromosomal Disease | WPHA/WNT Endorsed | 0.4 | KE:155 | Inadequate DNA repair |
KE:1636 | Increase, Chromosomal aberrations | |||||
AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | Under Development | 0.6 | KE:757 | Hippocampal anatomy, Altered |
KE:402 | Cognitive function, decreased | |||||
KE:756 | Hippocampal gene expression, Altered | |||||
AOP:302 | Lung surfactant function inhibition leading to decreased lung function | Respiratory System Disease | Under Development | 0.2 | KE:1250 | Decrease, Lung function |
AOP:312 | Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement | Unclassified | - | 0.17 | KE:351 | Increased Mortality |
AOP:313 | Stimulation of TLR7/8 in dendric cells leading to Psoriatic skin disease | Immune System Disease; Integumentary System Disease; Musculoskeletal System Disease | Under Development | 0.2 | KE:1709 | Psoriatic skin disease |
AOP:320 | Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality | Unclassified | Under Development | 0.33 | KE:1847 | Increased SARS-CoV-2 production |
KE:1750 | Increased inflammatory immune responses | |||||
KE:351 | Increased Mortality | |||||
AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive System Disease | - | 0.4 | KE:1757 | Reduce, Sperm count |
KE:155 | Inadequate DNA repair | |||||
AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | 0.12 | KE:351 | Increased Mortality |
AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.12 | KE:351 | Increased Mortality |
AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.12 | KE:351 | Increased Mortality |
AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular System Disease | Under Development | 0.43 | KE:1847 | Increased SARS-CoV-2 production |
KE:1869 | Diminished protective oxidative stress response | |||||
KE:1846 | Thrombosis and Disseminated Intravascular Coagulation | |||||
AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary System Disease | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1603 | Chronic kidney disease | |||||
AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | 0.25 | KE:1821 | Decrease, Cell proliferation |
KE:351 | Increased Mortality | |||||
AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive Disorder | - | 0.2 | KE:402 | Cognitive function, decreased |
AOP:406 | SARS-CoV-2 infection leading to hyperinflammation | Unclassified | - | 0.5 | KE:1868 | Hyperinflammation |
KE:1847 | Increased SARS-CoV-2 production | |||||
KE:1869 | Diminished protective oxidative stress response | |||||
AOP:410 | GSK3beta inactivation leading to increased mortality via defects in developing inner ear | Unclassified | - | 0.1 | KE:351 | Increased Mortality |
AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1670 | Lung cancer | |||||
AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | 0.2 | KE:1670 | Lung cancer |
AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory System Disease | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1250 | Decrease, Lung function | |||||
AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory System Disease | - | 0.5 | KE:1250 | Decrease, Lung function |
KE:1262 | Apoptosis | |||||
AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.5 | KE:870 | Increase, Cell Proliferation |
KE:1670 | Lung cancer | |||||
AOP:422 | Binding of SARS-CoV-2 to ACE2 in enterocytes leads to intestinal barrier disruption | Gastrointestinal System Disease | Under Development | 0.4 | KE:1847 | Increased SARS-CoV-2 production |
KE:1931 | Intestinal barrier, disruption | |||||
AOP:430 | Binding of SARS-CoV-2 to ACE2 leads to viral infection proliferation | Viral Infectious Disease | Under Development | 0.4 | KE:1847 | Increased SARS-CoV-2 production |
KE:1939 | Viral infection and host-to-host transmission, proliferated | |||||
AOP:431 | Increased tumor necrosis factor (TNF) leading to increased risk of gestational diabetes mellitus (GDM) | Inherited Metabolic Disorder | - | 0.4 | KE:1953 | Gestational diabetes mellitus |
KE:1952 | Abnormal, Glucose homeostasis | |||||
AOP:433 | hERG channel blockade leading to sudden cardiac death | Cardiovascular System Disease | - | 0.33 | KE:1961 | Prolongation of Action Potential Duration |
KE:1964 | Sudden cardiac death | |||||
AOP:442 | Binding to voltage gate sodium channels during development leads to cognitive impairment | Cognitive Disorder | Under Review | 0.29 | KE:757 | Hippocampal anatomy, Altered |
KE:402 | Cognitive function, decreased | |||||
AOP:449 | Ceramide synthase inhibition leading to neural tube defects | Neural Tube Defect | - | 0.14 | KE:1561 | Neural tube defects |
AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous System Disease | - | 0.57 | KE:352 | N/A, Neurodegeneration |
KE:1583 | Sensory axonal peripheral neuropathy | |||||
KE:351 | Increased Mortality | |||||
KE:1392 | Oxidative Stress | |||||
AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | 0.44 | KE:1115 | Increase, Reactive oxygen species |
KE:870 | Increase, Cell Proliferation | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1670 | Lung cancer | |||||
AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory System Disease | - | 0.27 | KE:2008 | Chronic obstructive pulmonary disease |
KE:1262 | Apoptosis | |||||
KE:1392 | Oxidative Stress | |||||
AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited Metabolic Disorder | - | 0.33 | KE:2119 | Insulin resistance, increased |
KE:1392 | Oxidative Stress | |||||
AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.25 | KE:402 | Cognitive function, decreased |
KE:756 | Hippocampal gene expression, Altered | |||||
AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.44 | KE:850 | Induction, CYP1A2/CYP1A5 |
KE:402 | Cognitive function, decreased | |||||
KE:756 | Hippocampal gene expression, Altered | |||||
KE:1392 | Oxidative Stress | |||||
AOP:468 | Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death) | Unclassified | - | 0.38 | KE:1868 | Hyperinflammation |
KE:1847 | Increased SARS-CoV-2 production | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | 0.2 | KE:885 | Increase, Cancer |
AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental Disorder Of Mental Health | Under Development | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental Disorder Of Mental Health | Under Review | 0.25 | KE:341 | Impairment, Learning and memory |
KE:1392 | Oxidative Stress | |||||
AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive Disorder | - | 0.14 | KE:402 | Cognitive function, decreased |
AOP:486 | Binding to the extracellular protein laminin leading to decreased cognitive function | Cognitive Disorder | - | 0.14 | KE:402 | Cognitive function, decreased |
AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental Disorder Of Mental Health | - | 0.27 | KE:2121 | decreased, Intellectual Quotient |
KE:188 | Neuroinflammation | |||||
KE:341 | Impairment, Learning and memory | |||||
AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive System Disease; Cancer | - | 0.44 | KE:286 | Altered, Transcription of genes by the androgen receptor |
KE:854 | Alterations, Cellular proliferation / hyperplasia | |||||
KE:1183 | Decreased, Apoptosis (Epithelial Cells) | |||||
KE:2135 | Prostate cancer | |||||
AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited Metabolic Disorder; Disease Of Metabolism | - | 0.62 | KE:2145 | Metabolic syndrome |
KE:1392 | Oxidative Stress | |||||
KE:177 | Mitochondrial dysfunction | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:2119 | Insulin resistance, increased | |||||
AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous System Disease | - | 0.5 | KE:191 | Neuronal dysfunction |
KE:2150 | Neurological disorder | |||||
AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous System Disease | - | 0.5 | KE:2150 | Neurological disorder |
KE:1392 | Oxidative Stress | |||||
AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.15 | KE:2115 | Altered, cholesterol metabolism |
KE:341 | Impairment, Learning and memory | |||||
AOP:530 | Endocytotic lysosomal uptake leads to intestinal barrier disruption | Gastrointestinal System Disease | - | 0.4 | KE:177 | Mitochondrial dysfunction |
KE:1931 | Intestinal barrier, disruption | |||||
AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.33 | KE:341 | Impairment, Learning and memory |
KE:1239 | Altered, Gene Expression | |||||
AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | 0.67 | KE:1115 | Increase, Reactive oxygen species |
KE:885 | Increase, Cancer | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
KE:1392 | Oxidative Stress | |||||
AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental Disorder Of Mental Health | - | 0.67 | KE:1262 | Apoptosis |
KE:2233 | Decreased, ERαβ heterodimers | |||||
KE:1392 | Oxidative Stress | |||||
KE:188 | Neuroinflammation | |||||
KE:341 | Impairment, Learning and memory | |||||
KE:2151 | Disruption, neurotransmitter release | |||||
AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.33 | KE:307 | Increase, Vitellogenin synthesis in liver |
KE:351 | Increased Mortality | |||||
AOP:539 | Decreased Sodium/Potassium ATPase activity leads to Heart failure | Cardiovascular System Disease | - | 0.29 | KE:2261 | Decreased, blood plasma volume |
KE:1535 | Heart failure | |||||
AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP:551 | Increased Muscarinic M2 Receptor leading to Arrhythmia | Symptom | - | 0.2 | KE:1106 | Occurrence, cardiac arrhythmia |
AOP:552 | Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP) | Cardiovascular System Disease | - | 0.17 | KE:1535 | Heart failure |
AOP:553 | Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure | Cardiovascular System Disease | - | 0.5 | KE:1532 | Decrease, Cardiac contractility |
KE:1535 | Heart failure | |||||
AOP:554 | β-adrenergic receptor agonists leading to arrhythmias. | Symptom | - | 0.25 | KE:1106 | Occurrence, cardiac arrhythmia |
AOP:555 | Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure | Cardiovascular System Disease | - | 0.6 | KE:2283 | Increased the early premature depolarizations during repolarization |
KE:1961 | Prolongation of Action Potential Duration | |||||
KE:1535 | Heart failure | |||||
AOP:556 | Decreased Na/K ATPase activity leading to heart failure | Cardiovascular System Disease | - | 0.33 | KE:1532 | Decrease, Cardiac contractility |
KE:1535 | Heart failure | |||||
AOP:558 | Phosphodiesterase inhibition leading to heart failure | Cardiovascular System Disease | - | 0.33 | KE:1532 | Decrease, Cardiac contractility |
KE:1535 | Heart failure | |||||
AOP:559 | Inhibition of acetylcholinesterase (AChE) leading to arrhythmias | Symptom | - | 0.2 | KE:1106 | Occurrence, cardiac arrhythmia |
AOP:560 | Inhibition of Funny current (If) leading to Arrhythmias | Symptom | - | 0.25 | KE:1106 | Occurrence, cardiac arrhythmia |
AOP:562 | HCN Channel Inhibition leading to Arrhythmias | Symptom | - | 0.2 | KE:1106 | Occurrence, cardiac arrhythmia |
AOP:564 | DBDPE-induced inhibition of mitochondrial complex Ⅰ leading to population decline via neurotoxicity and metabotoxicity. | Unclassified | - | 0.27 | KE:2151 | Disruption, neurotransmitter release |
KE:351 | Increased Mortality | |||||
KE:40 | Decrease, Mitochondrial ATP production | |||||
AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental Disorder Of Mental Health | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:2121 | decreased, Intellectual Quotient | |||||
AOP:572 | Imidacloprid-Induced BMP4 inhibition Leading to Neural Tube Closure Defects | Neural Tube Defect | - | 0.2 | KE:1561 | Neural tube defects |
AOP:573 | Inhibition, cytochrome oxidase leads to Increased, pulmonary edema | Respiratory System Disease | - | 0.33 | KE:2316 | Increased, pulmonary edema |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:7 | Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female | Reproductive System Disease; Endocrine System Disease; Reproductive System Disease | Under Review | 0.6 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:408 | reduction in ovarian granulosa cells, Aromatase (Cyp19a1) | |||||
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
AOP:62 | AKT2 activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.25 | KE:486 | systemic inflammation leading to hepatic steatosis |
AOP:69 | Modulation of Adult Leydig Cell Function Subsequent to Decreased Cholesterol Synthesis or Transport in the Adult Leydig Cell | Reproductive System Disease | - | 0.4 | KE:645 | Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells |
KE:642 | Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol | |||||
AOP:209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | Gastrointestinal System Disease | - | 0.38 | KE:1287 | Glutathione synthesis |
KE:1286 | Down Regulation, GSS and GSTs gene | |||||
KE:1284 | Up Regulation, SREBF2 | |||||
AOP:282 | Adverse outcome pathway on photochemical toxicity initiated by light exposure | Unclassified | Under Review | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:298 | Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer via chronic ROS | Cancer; Gastrointestinal System Disease | Under Review | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1753 | Chronic reactive oxygen species | |||||
AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:329 | Excessive reactive oxygen species production leading to mortality (3) | Unclassified | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1445 | Increase, Lipid peroxidation | |||||
AOP:330 | Excessive reactive oxygen species production leading to mortality (4) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary System Disease | - | 0.4 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
KE:177 | Mitochondrial dysfunction | |||||
AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:870 | Increase, Cell Proliferation | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1668 | Frustrated phagocytosis | |||||
AOP:423 | Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway | Unclassified | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:177 | Mitochondrial dysfunction | |||||
AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory System Disease | - | 0.5 | KE:1262 | Apoptosis |
KE:1392 | Oxidative Stress | |||||
KE:149 | Increase, Inflammation | |||||
KE:1445 | Increase, Lipid peroxidation | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1250 | Decrease, Lung function | |||||
KE:1239 | Altered, Gene Expression | |||||
KE:1993 | Increase, Pneumonia | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1198 | Activation, Macrophages | |||||
AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal System Disease | - | 0.38 | KE:1995 | Abnormal lipid metabolism |
KE:1392 | Oxidative Stress | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1931 | Intestinal barrier, disruption | |||||
KE:1198 | Activation, Macrophages | |||||
AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal System Disease | - | 0.38 | KE:1995 | Abnormal lipid metabolism |
KE:1392 | Oxidative Stress | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1931 | Intestinal barrier, disruption | |||||
KE:1198 | Activation, Macrophages | |||||
AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1262 | Apoptosis | |||||
KE:2040 | Decrease, GLI1/2 target gene expression | |||||
AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular System Disease | - | 0.19 | KE:1115 | Increase, Reactive oxygen species |
KE:177 | Mitochondrial dysfunction | |||||
KE:1392 | Oxidative Stress | |||||
AOP:523 | Retinoic acid receptor agonism during neurodevelopment leading to microcephaly | Congenital Nervous System Abnormality; Nervous System Disease | - | 0.2 | KE:2201 | Agonism, Retinoic acid receptor |
AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.56 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:1262 | Apoptosis | |||||
KE:1392 | Oxidative Stress | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:285 | Reduction, Vitellogenin synthesis in liver | |||||
AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular System Disease | - | 0.31 | KE:1115 | Increase, Reactive oxygen species |
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:1198 | Activation, Macrophages | |||||
KE:1392 | Oxidative Stress |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.75 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
KE:786 | Increase, Cytotoxicity (hepatocytes) | |||||
KE:787 | Increase, Regenerative cell proliferation (hepatocytes) | |||||
AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary System Disease | - | 0.6 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
KE:797 | Increase, Adenomas/carcinomas (urothelial) | |||||
KE:793 | Increase, Urinary bladder calculi | |||||
AOP:205 | AOP from chemical insult to cell death | Unclassified | - | 0.67 | KE:1259 | narcosis |
KE:177 | Mitochondrial dysfunction | |||||
KE:1262 | Apoptosis | |||||
KE:1263 | Necrosis | |||||
AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | 0.75 | KE:1821 | Decrease, Cell proliferation |
KE:1521 | Decrease, Growth | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.5 | KE:1521 | Decrease, Growth |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.5 | KE:1521 | Decrease, Growth |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.33 | KE:1521 | Decrease, Growth |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.6 | KE:1821 | Decrease, Cell proliferation |
KE:1521 | Decrease, Growth | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.5 | KE:1521 | Decrease, Growth |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | 0.71 | KE:870 | Increase, Cell Proliferation |
KE:1670 | Lung cancer | |||||
KE:1668 | Frustrated phagocytosis | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:1521 | Decrease, Growth | |||||
AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | 0.75 | KE:1115 | Increase, Reactive oxygen species |
KE:1521 | Decrease, Growth | |||||
KE:1445 | Increase, Lipid peroxidation | |||||
AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:1521 | Decrease, Growth | |||||
AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | 0.67 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1521 | Decrease, Growth | |||||
KE:1505 | Cell cycle, disrupted | |||||
AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 1.0 | KE:1521 | Decrease, Growth |
KE:1505 | Cell cycle, disrupted | |||||
KE:1445 | Increase, Lipid peroxidation | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1821 | Decrease, Cell proliferation | |||||
AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.8 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1521 | Decrease, Growth | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:392 | Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation | Unclassified | Under Development | 0.6 | KE:1868 | Hyperinflammation |
KE:1867 | Bradykinin system, hyperactivated | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:411 | Oxidative stress Leading to Decreased Lung Function | Respiratory System Disease | - | 0.5 | KE:1250 | Decrease, Lung function |
KE:1392 | Oxidative Stress | |||||
AOP:413 | Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure | Unclassified | - | 1.0 | KE:926 | Oxidation, Glutathione (To be considered with MIE) |
KE:351 | Increased Mortality | |||||
KE:1445 | Increase, Lipid peroxidation | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1607 | Increase, Necrosis | |||||
KE:759 | Increased, Kidney Failure | |||||
AOP:424 | Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction | Respiratory System Disease | - | 0.33 | KE:1250 | Decrease, Lung function |
KE:1392 | Oxidative Stress | |||||
AOP:425 | Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 | Respiratory System Disease | - | 0.33 | KE:1250 | Decrease, Lung function |
KE:1392 | Oxidative Stress | |||||
AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.5 | KE:1392 | Oxidative Stress |
KE:177 | Mitochondrial dysfunction | |||||
KE:1919 | Increased, Cardiac Dysregulation | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population | |||||
KE:1924 | Increased,Cardiac fibrosis | |||||
AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary System Disease | - | 0.25 | KE:177 | Mitochondrial dysfunction |
KE:1392 | Oxidative Stress | |||||
KE:759 | Increased, Kidney Failure | |||||
AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.41 | KE:2001 | Cardiac hypertrophy |
KE:1392 | Oxidative Stress | |||||
KE:1443 | Atherosclerosis | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population | |||||
KE:1924 | Increased,Cardiac fibrosis | |||||
KE:1198 | Activation, Macrophages | |||||
AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal System Disease | - | 0.55 | KE:1262 | Apoptosis |
KE:1392 | Oxidative Stress | |||||
KE:149 | Increase, Inflammation | |||||
KE:177 | Mitochondrial dysfunction | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:2034 | liver dysfunction | |||||
AOP:472 | DNA adduct formation leading to kidney failure | Urinary System Disease | - | 0.44 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1392 | Oxidative Stress | |||||
KE:759 | Increased, Kidney Failure | |||||
AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive Disorder | - | 0.57 | KE:1115 | Increase, Reactive oxygen species |
KE:1869 | Diminished protective oxidative stress response | |||||
KE:402 | Cognitive function, decreased | |||||
KE:1392 | Oxidative Stress | |||||
AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental Disorder Of Mental Health | - | 1.0 | KE:2146 | Activation of mitogen-activated protein kinase kinase, extracellular signal-regulated kinase 1/2 |
KE:1339 | Increase, intracellular calcium | |||||
KE:341 | Impairment, Learning and memory | |||||
KE:2151 | Disruption, neurotransmitter release | |||||
AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental Disorder Of Mental Health | - | 1.0 | KE:1262 | Apoptosis |
KE:2146 | Activation of mitogen-activated protein kinase kinase, extracellular signal-regulated kinase 1/2 | |||||
KE:177 | Mitochondrial dysfunction | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:352 | N/A, Neurodegeneration | |||||
KE:1339 | Increase, intracellular calcium | |||||
KE:341 | Impairment, Learning and memory | |||||
AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | 0.8 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:885 | Increase, Cancer | |||||
KE:1392 | Oxidative Stress | |||||
AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | 0.6 | KE:1115 | Increase, Reactive oxygen species |
KE:1060 | Alteration, lipid metabolism | |||||
KE:885 | Increase, Cancer | |||||
AOP:519 | Cardiac ion channels blockade leading to increased incidence of cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 1.0 | KE:1961 | Prolongation of Action Potential Duration |
KE:2282 | Cardiac ion channels blockade | |||||
KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population | |||||
KE:2283 | Increased the early premature depolarizations during repolarization | |||||
AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.4 | KE:2201 | Agonism, Retinoic acid receptor |
KE:341 | Impairment, Learning and memory | |||||
AOP:532 | Retinoic acid receptor agonism during cerebellar development leading to impaired locomotor function | Unclassified | - | 0.4 | KE:2201 | Agonism, Retinoic acid receptor |
KE:2231 | Locomotor function. Impaired | |||||
AOP:550 | Increased LMNA gene mutation leading to heart failure | Cardiovascular System Disease | - | 1.0 | KE:2066 | Altered Signaling Pathways |
KE:2279 | Structural changes in lamin A/C | |||||
KE:2278 | Increased LMNA Mutation | |||||
KE:1535 | Heart failure | |||||
KE:1924 | Increased,Cardiac fibrosis |
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.